Quantification of residual risk of relapse in breast cancer patients optimally treated

Breast

Volumn 22, Issue S2, 2013, Pages

  Dieci, Maria Vittoria ^a   Arnedos, Monica ^a   Delaloge, Suzette ^a   Andre, Fabrice ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Breast cancer; Chemotherapy; Endocrine therapy; Genomics; Lymphocytes

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PERTUZUMAB; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ALGORITHM; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CIRCULATING TUMOR CELL; GENOME ANALYSIS; GENOMICS; HEALTH CARE DELIVERY; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PATIENT SELECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

BREAST CANCER; CHEMOTHERAPY; ENDOCRINE THERAPY; GENOMICS; LYMPHOCYTES;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84884712520     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.017     Document Type: Article

References (19)

1. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001, 1:CD000486. Early Breast Cancer Trialists' Collaborative Group.
2. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. JClin Oncol 2010, 28:509-518.
3. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
4. Moja L., Tagliabue L., Balduzzi S., Parmelli E., Pistotti V., Guarneri V., et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012, 4:CD006243.
5. Roché H, Allouache D, Romieu G, Bourgeois H, Canon JL, Serin D, etal. Five year analysis of the FNCLCC-PACS04 Trial: FEC 100 vs ED75 for adjuvant treatment of node-positive breast cancer. In: Data presented at the 32nd annual San Antonio breast cancer symposium, 9-13 December 2009, San Antonio, Texas, USA. [Abstract 602].
6. [accessed 15.04.13]. http://seer.cancer.gov/statfacts/html/breast.html.
7. Dogan S., Dieci M.V., Goubar A., Arnedos M., Delaloge S., Andre F. Landscape and evolution of therapeutic research for breast cancer patients. Breast Cancer Res Treat 2013, 138:319-324.
8. Lucci A., Hall C.S., Lodhi A.K., Bhattacharyya A., Anderson A.E., Xiao L., et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012, 13:688-695.
9. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J., Wolmark N., et al. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). Cancer Res 2012, 72(Suppl.24). [Abstract S1-11].
10. Symmans W.F., Peintinger F., Hatzis C., Rajan R., Kuerer H., Valero V., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. JClin Oncol 2007, 25:4414-4422.
11. Ellis M.J., Tao Y., Luo J., A'Hern R., Evans D.B., Bhatnagar A.S., et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. JNatl Cancer Inst 2008, 100:1380-1388.
12. Mamounas E.P., Tang G., Paik S., Baehner F.L., Liu Q., Jeong J.-H., et al. Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): results from NSABP B-28. Cancer Res 2012, 72(Suppl.24). [Abstract S1-10].
13. Hatzis C., Pusztai L., Valero V., Booser D.J., Esserman L., Lluch A., et al. Agenomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAm Med Assoc 2011, 305:1873-1881.
14. Denkert C., Loibl S., Noske A., Roller M., Muller B.M., Komoret M., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. JClin Oncol 2010, 28:105-113.
15. Loi S., Michielis S., Lambrechts D., Salgado R., Sirtaine N., Fumagalli D., et al. Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): results from the FinHER trial. JClin Oncol 2012, 30(Suppl.). [abstr 507].
16. Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. JClin Oncol 2013, 31:860-867.
17. Andre F., Dieci M.V., Dubsky P., Sotiriou C., Curigliano G., Denkert C., et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 2013, 19:28-33.
18. Ignatiadis M., Singhal S.K., Desmedt C., Haibe-Kains B., Criscitiello C., Andre F., et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. JClin Oncol 2012, 30:1996-2004.
19. Birkbak N.J., Eklund A.C., Li Q., McClelland S.E., Endesfelder D., Tan P., et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011, 71:3447-3452.